Science1 distinct publisher3 min readPublished
The technique is 60 years old, the drainage rationale is plausible, and the evidence at the point of mass adoption was footage of a single patient. Controlled trials are only starting now.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
The diffusion mechanism here is more interesting than the surgical one. Deep cervical lymphatic-venous anastomosis needs no new molecule and no new skill: it is a vessel-joining technique developed in the 1960s for limb swelling after cancer surgery [16], aimed at a new target, the lymphatic drainage that carries waste out of the brain [3]. Any hospital with a microsurgeon can offer it. That is why hundreds of them in China were doing so soon after the footage began circulating [5][7]. Drugs move through regulators. Repurposed operations move through conference halls.
The paper trail behind the idea is short. In 2019 Xie was operating on a middle-aged woman with persistent tinnitus, noticed abnormal lymphatic structures deep in her neck, and rerouted lymph vessels into nearby veins to bypass them [15]. She reported afterwards that her mental acuity had improved along with her ears, and Xie then went looking in the literature for work that would explain it [17]. His 2022 report in a Chinese-language journal attracted little attention [4]. What moved the field was video, shown at surgical meetings from 2023 by Wei Chen of the Cleveland Clinic [5], who describes the response as jaws dropping and a frenzy of the surgery being performed left and right [6].
The most persuasive cut in that video is also its most awkward datum. The opening frame shows a man slumped and unresponsive; a jump cut three days later has him alert and naming his son [1][2]. Clinicians told Nature that mechanistic explanations are hard to square with improvement that fast [12]. Whatever changed in 72 hours, it is difficult to call it the clearance of accumulated waste protein, which is what the rationale actually proposes [3]. So the fast responders are simultaneously the part of the case that most needs a control arm and the part most likely to end up in a testimonial clip on Douyin [7].
Then the bill. Many patients paid more than 200,000 yuan, about US$30,000 [7]. Take a thousand patients, the floor of "thousands", and that is on the order of $30 million of household money [18] spent on something Chinese regulators subsequently confined to formal research settings [8]. Young-Kwon Hong, a lymphatics researcher at Beth Israel Deaconess Medical Center, told Nature the concept is scientifically valid and biologically plausible, and also that hope this high brings hype with it [14]. Both halves of that sentence are doing work.
None of the thousands already operated on will settle the question, because the scale arrived before any controlled study did [19]. The trials now recruiting [10] will report modest numbers against footage of a man walking briskly down a corridor reciting a military anthem from memory [2], while the surgeon who started it has been in detention since September for reasons nobody has disclosed [9].
Ranked by verification strength, evidence, and original report placement.
In September 2020 a man in his 80s became the first person in the world to undergo deep cervical lymphatic-venous anastomosis (dcLVA) to treat Alzheimer's disease; a video documents his recovery, opening with him slumped in a hospital bed.
In the footage, a jump cut advances three days to the man alert and identifying his son; at six months he sits upright in conversation; at eight months he walks briskly down a hospital corridor and recites a near-century-old Maoist military anthem from memory.
dcLVA connects tiny lymphatic vessels in the neck, part of the drainage system carrying waste away from the brain, to nearby veins, creating a route that in theory lets fluid and waste proteins flow more easily into the bloodstream.
The treatment was first reported in 2022 in a Chinese-language journal by microsurgeon Qingping Xie, president of the Qiushi Hospital in Hangzhou, China, and at the time drew little notice.
The following year, Wei Chen, a lymphatic microsurgeon at the Cleveland Clinic in Ohio, began showing the footage at surgical meetings around the world, with consent from Xie and the man's family.
Chen: "A lot of jaws dropped. It basically started a frenzy of this surgery being performed left and right."
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
One patient on video plus animal-model rationale
The efficacy evidence at the point of mass diffusion was a single patient's before/after footage, supported by a plausible drainage mechanism drawn from meningeal-lymphatic and glymphatic research and a 60-year-old surgical technique. No controlled results, cohort outcomes or complication rates appear anywhere in the cluster; clinicians in the same article say the mechanism does not fit the speed of improvement, and controlled studies are only beginning.
Mass clinical uptake, now regulator-constrained
Hundreds of hospitals offered the procedure, thousands of patients sought it, and Xie alone had over 60 cases by early 2023, with many patients paying about US$30,000 out of pocket. Adoption is heavily concentrated in one country and has since been pushed back into research settings by regulators, which caps the score below the top band.
Claims of reversal far ahead of data
Symptom-reversal narratives, viral testimonials and US$30,000 price points ran ahead of any controlled result; the cluster's own expert framing is that the concept is plausible but 'whenever hope is high, the hype also follows', and regulators acted specifically on adoption 'in the absence of hard evidence'. The gap is positive and large, though not maximal, because the biological rationale is real and peer-reviewed groundwork exists.
Direct-pay revenue and promotional marketing
The cluster documents strong commercial and reputational incentives on the supply side: patient payments above 200,000 yuan (~US$30,000) largely out of pocket, hundreds of hospitals competing to offer the procedure, aggressive Douyin and WeChat marketing with viral testimonials, an originator who is also a hospital president, and a surgeon-advocate presenting the footage at meetings worldwide. Desperation among Alzheimer's families is an unusually strong demand-side incentive. Precise revenue and vendor economics are not disclosed, so this is a directional rather than audited reading.
One outlet, but broad expert sourcing
Only a single publisher is in the cluster, so no cross-outlet corroboration of the adoption figures, the regulatory restriction or the detention is available. Confidence is nonetheless moderate because the reporting discloses its basis: more than two dozen researchers interviewed, named experts on the record, Xie's pre-detention interviews corroborated by his daughter, and cited peer-reviewed underpinnings. Key numbers remain qualitative ('hundreds', 'thousands'), and dates for the restriction and detention are relative rather than explicit.
science
Rydberg chain spectra match Ising CFT predictions, turning a simulator into an instrument1 distinct publisher
science
Sleep tech turns rest into evidence, and employers are the ones who will need rules1 distinct publisher
science
South Africa moves to license its scientists, with a year in jail for the unregistered1 distinct publisher
science
The EU AI Office can now fine and recall. The evidence has to come from somewhere1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.